GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (NAS:ALKS) » Definitions » E10
中文

Alkermes (Alkermes) E10 : $-0.76 (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Alkermes E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Alkermes's adjusted earnings per share data for the three months ended in Dec. 2023 was $0.660. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.76 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 1.30% per year. During the past 5 years, the average E10 Growth Rate was -2.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Alkermes was 60.70% per year. The lowest was -225.50% per year. And the median was -0.65% per year.

As of today (2024-04-25), Alkermes's current stock price is $24.65. Alkermes's E10 for the quarter that ended in Dec. 2023 was $-0.76. Alkermes's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Alkermes was 3677.06. The lowest was 467.48. And the median was 653.80.


Alkermes E10 Historical Data

The historical data trend for Alkermes's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes E10 Chart

Alkermes Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.78 -0.79 -0.80 -0.92 -0.76

Alkermes Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.92 -0.96 -0.85 -0.82 -0.76

Competitive Comparison of Alkermes's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkermes's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkermes's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Alkermes's Shiller PE Ratio falls into.



Alkermes E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Alkermes's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.66/120.1096*120.1096
=0.660

Current CPI (Dec. 2023) = 120.1096.

Alkermes Quarterly Data

per share eps CPI Adj_EPS
201403 -0.170 100.573 -0.203
201406 0.020 100.773 0.024
201409 -0.270 100.474 -0.323
201412 0.200 99.576 0.241
201503 -0.210 99.975 -0.252
201506 -0.310 100.573 -0.370
201509 -0.540 100.274 -0.647
201512 -0.460 99.676 -0.554
201603 -0.510 99.676 -0.615
201606 -0.310 101.072 -0.368
201609 -0.410 100.274 -0.491
201612 -0.140 99.676 -0.169
201703 -0.450 100.374 -0.538
201706 -0.280 100.673 -0.334
201709 -0.240 100.474 -0.287
201712 -0.060 100.075 -0.072
201803 -0.400 100.573 -0.478
201806 -0.210 101.072 -0.250
201809 -0.220 101.371 -0.261
201812 -0.060 100.773 -0.072
201903 -0.620 101.670 -0.732
201906 -0.270 102.168 -0.317
201909 -0.340 102.268 -0.399
201912 -0.030 102.068 -0.035
202003 -0.240 102.367 -0.282
202006 -0.190 101.769 -0.224
202009 -0.001 101.072 -0.001
202012 -0.270 101.072 -0.321
202103 -0.140 102.367 -0.164
202106 0.010 103.364 0.012
202109 -0.180 104.859 -0.206
202112 0.010 106.653 0.011
202203 -0.220 109.245 -0.242
202206 -0.180 112.734 -0.192
202209 -0.390 113.431 -0.413
202212 -0.170 115.425 -0.177
202303 -0.250 117.618 -0.255
202306 1.380 119.611 1.386
202309 0.280 120.708 0.279
202312 0.660 120.110 0.660

Add all the adjusted EPS together and divide 10 will get our e10.


Alkermes  (NAS:ALKS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Alkermes was 3677.06. The lowest was 467.48. And the median was 653.80.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Alkermes E10 Related Terms

Thank you for viewing the detailed overview of Alkermes's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Alkermes (Alkermes) Business Description

Traded in Other Exchanges
Address
1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
Executives
Cato T Laurencin director C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
Christian Todd Nichols officer: SVP, Chief Commercial Officer 852 WINTER STREET, WALTHAM MA 02451
Nancy Wysenski director 2200 SUNBURST STREET, CHATSWORTH CA 90401
Daglio David Angelo Jr. director ALKERMES, 852 WINTER STREET, WALTHAM MA 02451
Christopher I Wright director C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Michael J Landine officer: SVP, Corp Dev., Alkermes, Inc. 88 SIDNEY ST, CAMBRIDGE MA 021394136
Richard F Pops director, officer: Director and CEO, Alkermes plc 10555 SCIENCE CENTER DR, SAN DIEGO CA 92121
Shane Cooke officer: President, Alkermes plc TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Blair Curtis Jackson officer: EVP, Chief Operating Officer 852 WINTER STREET, WALTHAM MA 02451
Snyderman Nancy Lynn Md director 37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Craig C. Hopkinson officer: SVP, Med Dev/Med Affairs, CMO 852 WINTER STREET, WALTHAM MA 02451
Emily Peterson Alva director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Iain Michael Brown officer: VP, Finance & CAO 14 ROYALSTON AVENUE, WINCHESTER MA 01890
Brian P Mckeon director IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
David Joseph Gaffin officer: SVP, CLO, Alkermes, Inc. 852 WINTER STREET, WALTHAM MA 02451